Takeda's Rich Pipeline Optionality Is Worth A 'Buy' (NYSE:TAK)
· seekingalpha.com
Takeda (TAK) FY2025 outlook: revenue dip from Vyvanse generics, $1.3B cost-savings plan, and 3 key launches.
Takeda Pharmaceutical Company Limited ( TAK ) is a global Japanese pharmaceutical company with multiple established products. Their revenues have recently been ...